Effects of GSK598809 on Brain Activation in Abstinent Alcoholics
|ClinicalTrials.gov Identifier: NCT00908206|
Recruitment Status : Withdrawn (Study not approved by BfARM)
First Posted : May 25, 2009
Last Update Posted : April 17, 2015
This study will compare the effects of GSK598809 and placebo in alcohol dependent volunteers. A placebo is a pill with no drug in it (i.e. dummy drug) but it is made to look exactly like the real drug.
Subjects will be given one dose of GSK598809 during one visit and placebo during the other visit. These dosing visits will be at least 1 week apart. The study is randomised, which means that a computer programme will decide by chance (like tossing a coin), the order in which subjects will receive GSK598809 or the placebo, or in other words, whether they will receive GSK598809 or placebo first.
The study is blinded, which means the subjects will not know whether they are receiving study drug or placebo first and neither will the doctors at the institute. If necessary for reasons of safety, the study staff can find out exactly what the subject has received.
The study will last for approximately 4 weeks but could be up to 6 weeks, depending on length of time between screening and dosing. From screening the subjects will be alcohol-abstinent, they may be put on medication for treatment of withdrawal symptoms and then will have at least 7 days without any medication before beginning the study medication. During the study the subjects will be inpatients at the Central Institute of Mental Health. All subjects will be required to fill out questionnaires, perform behavioural tasks and undergo MRI and functional MRI (fMRI) scans.
|Condition or disease||Intervention/treatment||Phase|
|Substance Dependence Alcohol Dependence||Drug: GSK598809||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Placebo-controlled, Single-blind, Cross-over, Randomised, fMRI Study Comparing Cue-induced Brain Activation Patterns After a Single Oral Dose of GSK598809 or Placebo in Abstinent Alcoholic Subjects|
|Study Start Date :||May 2009|
|Primary Completion Date :||July 2009|
|Study Completion Date :||July 2009|
Placebo Comparator: Placebo
Placebo to match GSK598809.
Subjects will receive a single 175 mg oral dose of GSK598809.
- BOLD signal changes in the relevant brain areas following presentation of visual alcohol-related vs neutral, non-alcohol related cues. [ Time Frame: 1.5h (± 0.5h) after each dose (2 doses) ]
- BOLD signal changes in the same brain structures and circuits as above during a Monetary Incentive Delay task. [ Time Frame: 1.5h (± 0.5h) after each dose (2 doses) ]
- Subjective craving in response to alcohol-related cues measured with the Alcohol Urge Questionnaire (AUQ) and the Obsessive Compulsive Drinking Scale (OCDS). [ Time Frame: Screening and pre-scan. ]
- Spontaneously reported adverse events, laboratory values, cardiovascular variables (blood pressure, heart rate, and ECG variables), temperature, respiratory rate, serum prolactin concentrations, TSH, testosterone, LH and FSH. [ Time Frame: Throughout study. ]
- Pharmacokinetic parameters of GSK598809 and its metabolite GSK685249: AUC (0-∞), Cmax, tmax, t½. [ Time Frame: Pre-dose to 48h post dose. ]
- Pair-wise correlation of BOLD signal changes in different image voxels and between selected brain structures during the alcohol-related cue paradigm and the Monetary Incentive Delay task, and in the brain resting state. [ Time Frame: 1.5h (± 0.5h) after each dose (2 doses) ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00908206
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|